Ontology type: schema:ScholarlyArticle Open Access: True
2006-07-18
AUTHORSV Lévy, S Zohar, C Bardin, A Vekhoff, D Chaoui, B Rio, O Legrand, S Sentenac, P Rousselot, E Raffoux, F Chast, S Chevret, J P Marie
ABSTRACTTo determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine (ssHHT), given as a twice daily subcutaneous (s.c.) injections for 9 days, in patients with advanced acute leukaemia, 18 patients with advanced acute myeloid leukaemia were included in this sequential Bayesian phase I dose-finding trial. A starting dose of 0.5 mg m−2 day−1 was explored with subsequent dose escalations of 1, 3, 5 and 6 mg m−2 day−1. Myelosuppression was constant. The MTD was estimated as the dose level of 5 mg m−2 day−1 for 9 consecutive days by s.c. route. Dose-limiting toxicities were hyperglycaemia with hyperosmolar coma at 3 mg m−2, and (i) one anasarque and haematemesis, (ii) one life-threatening pulmonary aspergillosis, (iii) one skin rash and (iv) one scalp pain at dose level of 5 mg m−2 day−1. The mean half-life of ssHHT was 11.01±3.4 h, the volume of distribution at steady state was 2±1.4 l kg−1 and the plasma clearance was 11.6±10.4 l h−1. Eleven of the 12 patients with circulating leukaemic cells had blood blast clearance, two achieved complete remission and one with blast crisis of CMML returned in chronic phase. The recommended daily dose of ssHHT on the 9-day schedule is 5 mg m−2 day−1. More... »
PAGES253-259
http://scigraph.springernature.com/pub.10.1038/sj.bjc.6603265
DOIhttp://dx.doi.org/10.1038/sj.bjc.6603265
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1030793270
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/16847470
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Acute Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Dose-Response Relationship, Drug",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Administration Schedule",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Harringtonines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Homoharringtonine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Injections, Subcutaneous",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myeloid",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Maximum Tolerated Dose",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Remission Induction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Survival Rate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Inserm U717, H\u00f4pital Saint Louis, Paris, France",
"id": "http://www.grid.ac/institutes/grid.413328.f",
"name": [
"Inserm CIC 9504, Centre d'Investigations Cliniques, H\u00f4pital Saint Louis, AP-HP, 1 Avenue Claude Vellefaux, 75475, Paris, France",
"Inserm U717, H\u00f4pital Saint Louis, Paris, France"
],
"type": "Organization"
},
"familyName": "L\u00e9vy",
"givenName": "V",
"id": "sg:person.01105023444.16",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105023444.16"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "D\u00e9partement de Biostatistique et Infomatique M\u00e9dicale, Inserm U717, H\u00f4pital Saint Louis, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.413328.f",
"name": [
"Inserm CIC 9504, Centre d'Investigations Cliniques, H\u00f4pital Saint Louis, AP-HP, 1 Avenue Claude Vellefaux, 75475, Paris, France",
"Inserm U717, H\u00f4pital Saint Louis, Paris, France",
"D\u00e9partement de Biostatistique et Infomatique M\u00e9dicale, Inserm U717, H\u00f4pital Saint Louis, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Zohar",
"givenName": "S",
"id": "sg:person.01207514343.96",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207514343.96"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service de Pharmacie Pharmacologie Toxicologie, H\u00f4tel Dieu de Paris, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.411394.a",
"name": [
"Service de Pharmacie Pharmacologie Toxicologie, H\u00f4tel Dieu de Paris, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Bardin",
"givenName": "C",
"id": "sg:person.0717466254.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717466254.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.411394.a",
"name": [
"D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Vekhoff",
"givenName": "A",
"id": "sg:person.01362131264.28",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362131264.28"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.411394.a",
"name": [
"D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Chaoui",
"givenName": "D",
"id": "sg:person.01163646352.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163646352.37"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.411394.a",
"name": [
"D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Rio",
"givenName": "B",
"id": "sg:person.01245127334.86",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245127334.86"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.411394.a",
"name": [
"D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Legrand",
"givenName": "O",
"id": "sg:person.0752753564.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service de Pharmacie Pharmacologie Toxicologie, H\u00f4tel Dieu de Paris, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.411394.a",
"name": [
"Service de Pharmacie Pharmacologie Toxicologie, H\u00f4tel Dieu de Paris, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Sentenac",
"givenName": "S",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service d'H\u00e9matologie Clinique, H\u00f4pital Saint Louis, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.413328.f",
"name": [
"Service d'H\u00e9matologie Clinique, H\u00f4pital Saint Louis, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Rousselot",
"givenName": "P",
"id": "sg:person.01063057420.66",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063057420.66"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service d'H\u00e9matologie Clinique, H\u00f4pital Saint Louis, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.413328.f",
"name": [
"Service d'H\u00e9matologie Clinique, H\u00f4pital Saint Louis, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Raffoux",
"givenName": "E",
"id": "sg:person.01241622025.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241622025.01"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service de Pharmacie Pharmacologie Toxicologie, H\u00f4tel Dieu de Paris, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.411394.a",
"name": [
"Service de Pharmacie Pharmacologie Toxicologie, H\u00f4tel Dieu de Paris, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Chast",
"givenName": "F",
"id": "sg:person.065721244.52",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.065721244.52"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "D\u00e9partement de Biostatistique et Infomatique M\u00e9dicale, Inserm U717, H\u00f4pital Saint Louis, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.413328.f",
"name": [
"Inserm U717, H\u00f4pital Saint Louis, Paris, France",
"D\u00e9partement de Biostatistique et Infomatique M\u00e9dicale, Inserm U717, H\u00f4pital Saint Louis, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Chevret",
"givenName": "S",
"id": "sg:person.0625147223.89",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625147223.89"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France",
"id": "http://www.grid.ac/institutes/grid.411394.a",
"name": [
"D\u00e9partement d'H\u00e9matologie et d'Oncologie M\u00e9dicale, H\u00f4tel Dieu, AP-HP, Paris, France"
],
"type": "Organization"
},
"familyName": "Marie",
"givenName": "J P",
"id": "sg:person.01064502270.46",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064502270.46"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/bf00267945",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017207622",
"https://doi.org/10.1007/bf00267945"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.leu.2400608",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052204571",
"https://doi.org/10.1038/sj.leu.2400608"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.leu.2402067",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014124550",
"https://doi.org/10.1038/sj.leu.2402067"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00258117",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045840021",
"https://doi.org/10.1007/bf00258117"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.bjc.6602969",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013557227",
"https://doi.org/10.1038/sj.bjc.6602969"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00179432",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018224236",
"https://doi.org/10.1007/bf00179432"
],
"type": "CreativeWork"
}
],
"datePublished": "2006-07-18",
"datePublishedReg": "2006-07-18",
"description": "To determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine (ssHHT), given as a twice daily subcutaneous (s.c.) injections for 9 days, in patients with advanced acute leukaemia, 18 patients with advanced acute myeloid leukaemia were included in this sequential Bayesian phase I dose-finding trial. A starting dose of 0.5\u2009mg\u2009m\u22122\u2009day\u22121 was explored with subsequent dose escalations of 1, 3, 5 and 6\u2009mg\u2009m\u22122\u2009day\u22121. Myelosuppression was constant. The MTD was estimated as the dose level of 5\u2009mg\u2009m\u22122\u2009day\u22121 for 9 consecutive days by s.c. route. Dose-limiting toxicities were hyperglycaemia with hyperosmolar coma at 3\u2009mg\u2009m\u22122, and (i) one anasarque and haematemesis, (ii) one life-threatening pulmonary aspergillosis, (iii) one skin rash and (iv) one scalp pain at dose level of 5\u2009mg\u2009m\u22122\u2009day\u22121. The mean half-life of ssHHT was 11.01\u00b13.4\u2009h, the volume of distribution at steady state was 2\u00b11.4\u2009l\u2009kg\u22121 and the plasma clearance was 11.6\u00b110.4\u2009l\u2009h\u22121. Eleven of the 12 patients with circulating leukaemic cells had blood blast clearance, two achieved complete remission and one with blast crisis of CMML returned in chronic phase. The recommended daily dose of ssHHT on the 9-day schedule is 5\u2009mg\u2009m\u22122\u2009day\u22121.",
"genre": "article",
"id": "sg:pub.10.1038/sj.bjc.6603265",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1017082",
"issn": [
"0007-0920",
"1532-1827"
],
"name": "British Journal of Cancer",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "3",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "95"
}
],
"keywords": [
"maximum-tolerated dose",
"advanced acute myeloid leukemia",
"acute myeloid leukemia",
"myeloid leukemia",
"dose levels",
"advanced acute leukemia",
"subsequent dose escalation",
"dose-limiting toxicity",
"daily subcutaneous injections",
"volume of distribution",
"dose-finding trial",
"phase I dose-finding trials",
"semisynthetic homoharringtonine",
"scalp pain",
"starting dose",
"complete remission",
"skin rash",
"blast clearance",
"dose escalation",
"daily dose",
"pulmonary aspergillosis",
"chronic phase",
"acute leukemia",
"subcutaneous injection",
"plasma clearance",
"blast crisis",
"leukaemic cells",
"patients",
"consecutive days",
"dose",
"leukemia",
"pharmacokinetic study",
"clearance",
"homoharringtonine",
"toxicity",
"days",
"haematemesis",
"myelosuppression",
"remission",
"hyperglycaemia",
"rash",
"pain",
"aspergillosis",
"CMML",
"hyperosmolar",
"trials",
"levels",
"injection",
"escalation",
"cells",
"schedule",
"study",
"volume",
"steady state",
"phase",
"state",
"distribution",
"crisis"
],
"name": "A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia",
"pagination": "253-259",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1030793270"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/sj.bjc.6603265"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"16847470"
]
}
],
"sameAs": [
"https://doi.org/10.1038/sj.bjc.6603265",
"https://app.dimensions.ai/details/publication/pub.1030793270"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:23",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_421.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1038/sj.bjc.6603265"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603265'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603265'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603265'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603265'
This table displays all metadata directly associated to this object as RDF triples.
309 TRIPLES
22 PREDICATES
108 URIs
93 LITERALS
24 BLANK NODES